Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Paclitaxel and docetaxel are excellent agents with a high antitumor effect for the treatment of previously anthracycline-exposed metastatic breast cancer. There has been no standard treatment for patients who undergo therapy of a taxan-resistant metastatic breast cancer. Paclitaxel has partial non-cross-resistance in vitro with docetaxel in inhibiting microtubule disaggregation. We present the case of a patient with docetaxel-refractory anthracycline-pretreated metastatic breast cancer who achieved remission with paclitaxel.
Suzuma
T
T
Department of Surgery, Affiliated Kihoku Hospital, Wakayama Medical College, Itogun, Japan. suzuma@mail.wakayama-med.ac.jp
Sakurai
T
T
Yoshimura
G
G
Umemura
T
T
Tamaki
T
T
Naito
Y
Y
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D043823:Taxoids
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel